Daniel K. Kajdasz

2.7k total citations
41 papers, 1.9k citations indexed

About

Daniel K. Kajdasz is a scholar working on Pharmacology, Psychiatry and Mental health and Cognitive Neuroscience. According to data from OpenAlex, Daniel K. Kajdasz has authored 41 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Pharmacology, 22 papers in Psychiatry and Mental health and 13 papers in Cognitive Neuroscience. Recurrent topics in Daniel K. Kajdasz's work include Treatment of Major Depression (18 papers), Pain Management and Placebo Effect (11 papers) and Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes (9 papers). Daniel K. Kajdasz is often cited by papers focused on Treatment of Major Depression (18 papers), Pain Management and Placebo Effect (11 papers) and Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes (9 papers). Daniel K. Kajdasz collaborates with scholars based in United States, United Kingdom and Germany. Daniel K. Kajdasz's co-authors include Amy S. Chappell, Daniel Walker, Madelaine M. Wohlreich, Philip J. Mease, Michael J. Detke, Lesley M. Arnold, Joel Raskin, Joachim Wernicke, Timothy R. Smith and D. Desaiah and has published in prestigious journals such as American Journal of Epidemiology, Pain and Anesthesiology.

In The Last Decade

Daniel K. Kajdasz

40 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Daniel K. Kajdasz United States 24 1.1k 821 426 321 221 41 1.9k
Martin Birkett United States 20 367 0.3× 773 0.9× 371 0.9× 103 0.3× 212 1.0× 26 2.3k
Mehrul Hasnain United States 20 587 0.5× 692 0.8× 150 0.4× 131 0.4× 231 1.0× 35 1.9k
Gwen L. Zornberg United States 15 404 0.4× 692 0.8× 149 0.3× 195 0.6× 370 1.7× 23 1.9k
Margaret A. Kirshner United States 26 480 0.4× 946 1.2× 120 0.3× 151 0.5× 94 0.4× 40 2.1k
Brandon Walsh United States 14 748 0.7× 247 0.3× 275 0.6× 369 1.1× 171 0.8× 15 2.3k
Norman Rosenthal United States 35 1.1k 1.0× 822 1.0× 810 1.9× 315 1.0× 72 0.3× 59 4.1k
Richard C. Risser United States 31 676 0.6× 2.6k 3.2× 372 0.9× 107 0.3× 162 0.7× 48 4.2k
Paul Kudlow Canada 13 350 0.3× 343 0.4× 199 0.5× 304 0.9× 310 1.4× 25 2.9k
Peter Manu United States 29 314 0.3× 2.2k 2.7× 425 1.0× 112 0.3× 138 0.6× 108 3.2k
Einat Peles Israel 28 400 0.4× 241 0.3× 330 0.8× 328 1.0× 348 1.6× 109 2.6k

Countries citing papers authored by Daniel K. Kajdasz

Since Specialization
Citations

This map shows the geographic impact of Daniel K. Kajdasz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel K. Kajdasz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel K. Kajdasz more than expected).

Fields of papers citing papers by Daniel K. Kajdasz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel K. Kajdasz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel K. Kajdasz. The network helps show where Daniel K. Kajdasz may publish in the future.

Co-authorship network of co-authors of Daniel K. Kajdasz

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel K. Kajdasz. A scholar is included among the top collaborators of Daniel K. Kajdasz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel K. Kajdasz. Daniel K. Kajdasz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bennett, Robert M., I. Jon Russell, Ernest Choy, et al.. (2012). Evaluation of Patient-Rated Stiffness Associated With Fibromyalgia: A Post-Hoc Analysis of 4 Pooled, Randomized Clinical Trials of Duloxetine. Clinical Therapeutics. 34(4). 824–837. 20 indexed citations
2.
Reed, Carol R., et al.. (2011). The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder. Current Medical Research and Opinion. 28(1). 27–39. 20 indexed citations
3.
Khan, Arif, Andrew J. Cutler, Daniel K. Kajdasz, et al.. (2011). A Randomized, Double-Blind, Placebo-Controlled, 8-Week Study of Vilazodone, a Serotonergic Agent for the Treatment of Major Depressive Disorder. The Journal of Clinical Psychiatry. 72(4). 441–447. 106 indexed citations
4.
Arnold, Lesley M., James I. Hudson, Fujun Wang, et al.. (2009). Comparisons of the Efficacy and Safety of Duloxetine for the Treatment of Fibromyalgia in Patients With Versus Without Major Depressive Disorder. Clinical Journal of Pain. 25(6). 461–468. 21 indexed citations
5.
Chappell, Amy S., G. Littlejohn, Daniel K. Kajdasz, et al.. (2009). A 1-year Safety and Efficacy Study of Duloxetine in Patients With Fibromyalgia. Clinical Journal of Pain. 25(5). 365–375. 53 indexed citations
6.
Fishbain, David A., Michael J. Detke, Joachim Wernicke, Amy S. Chappell, & Daniel K. Kajdasz. (2008). The relationship between antidepressant and analgesic responses: findings from six placebo-controlled trials assessing the efficacy of duloxetine in patients with major depressive disorder. Current Medical Research and Opinion. 24(11). 3105–3115. 24 indexed citations
7.
Brecht, Stephan, Daniel K. Kajdasz, Susan Ball, & Michael E. Thase. (2008). Clinical impact of duloxetine treatment on sleep in patients with major depressive disorder. International Clinical Psychopharmacology. 23(6). 317–324. 9 indexed citations
8.
9.
Raskin, Joel, Jimmy Yu Xu, & Daniel K. Kajdasz. (2007). Time to response for duloxetine 60 mg once daily versus placebo in elderly patients with major depressive disorder. International Psychogeriatrics. 20(2). 309–327. 22 indexed citations
10.
Armstrong, David G., Amy S. Chappell, Trong Kim Le, et al.. (2007). Duloxetine for the Management of Diabetic Peripheral Neuropathic Pain: Evaluation of Functional Outcomes. Pain Medicine. 8(5). 410–418. 27 indexed citations
11.
Wernicke, Joachim, et al.. (2007). An Evaluation of the Cardiovascular Safety Profile of Duloxetine. Drug Safety. 30(5). 437–455. 100 indexed citations
12.
13.
Pérahia, David, Daniel K. Kajdasz, Daniel Walker, Joel Raskin, & André Tylee. (2006). Duloxetine 60 mg once daily in the treatment of milder major depressive disorder. International Journal of Clinical Practice. 60(5). 613–620. 23 indexed citations
14.
Pérahia, David, et al.. (2006). Duloxetine in the treatment of major depressive disorder: an assessment of the relationship between outcomes and episode characteristics. International Clinical Psychopharmacology. 21(5). 285–295. 15 indexed citations
15.
Hudson, James I., Madelaine M. Wohlreich, Daniel K. Kajdasz, et al.. (2005). Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo‐controlled clinical trials. Human Psychopharmacology Clinical and Experimental. 20(5). 327–341. 99 indexed citations
16.
Dünner, David L., Deborah N. D’Souza, Daniel K. Kajdasz, Michael J. Detke, & James M. Russell. (2005). Is treatment-associated hypomania rare with duloxetine: Secondary analysis of controlled trials in non-bipolar depression. Journal of Affective Disorders. 87(1). 115–119. 24 indexed citations
17.
Pérahia, David, Daniel K. Kajdasz, D. Desaiah, & Peter Haddad. (2005). Symptoms following abrupt discontinuation of duloxetine treatment in patients with major depressive disorder. Journal of Affective Disorders. 89(1-3). 207–212. 63 indexed citations
18.
Kajdasz, Daniel K., Marc A. Judson, Lawrence C. Mohr, & Daniel T. Lackland. (1999). Geographic Variation in Sarcoidosis in South Carolina: Its Relation to Socioeconomic Status and Health Care Indicators. American Journal of Epidemiology. 150(3). 271–278. 39 indexed citations
19.
Malcolm, Robert, et al.. (1999). Amlodipine Treatment of Cocaine Dependence. Journal of Psychoactive Drugs. 31(2). 117–120. 9 indexed citations
20.
Malcolm, Robert, et al.. (1997). Pergolide Mesylate: Adverse Events Occurring in the Treatment of Cocaine Dependence. American Journal on Addictions. 6(2). 117–123. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Martin Birkett Breakdown of academic impact, for papers by Mehrul Hasnain Breakdown of academic impact, for papers by Gwen L. Zornberg Breakdown of academic impact, for papers by Margaret A. Kirshner Breakdown of academic impact, for papers by Brandon Walsh Breakdown of academic impact, for papers by Norman Rosenthal Breakdown of academic impact, for papers by Richard C. Risser Breakdown of academic impact, for papers by Paul Kudlow Breakdown of academic impact, for papers by Peter Manu Breakdown of academic impact, for papers by Einat Peles
Rankless by CCL
2026